Search
Janux Therapeutics Inc
JANXAdd to Watchlist
16.930USD
-0.030-0.18%
Close 10-02 16:00（ET）
1.03BMarket Cap
LossP/E TTM
Janux Therapeutics Inc (JANX) Stock Price Target & Forecast
Analyst Rating
Based on 20 analysts giving stock ratings to Janux Therapeutics Inc in the past month.
Buy
7 Strong Buy
9 Buy
3 Hold
1 Sell
0 Strong Sell
Target Price
36.389USD+114.94%
JANX Analyst Recommendation Trends
In the current month, JANX has received 9 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. JANX average Analyst price target in the last month is 36.389.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
7
7
7
7
7
7
7
7
9
9
9
11
11
11
12
12
3
3
3
2
2
2
1
1
0
0
0
0
0
0
0
0
1
1
1
0
0
0
0
0
20
20
20
20
20
20
20
20
JANX Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, JANX EPS is projected to reach -0.475 in FY2026Q3, following reported EPS of -0.349 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.64
-0.53
-0.38
-0.47
-0.53
Actual
-0.51
-0.39
-0.35
--
--
Surprise
+20.20%
+26.15%
+9.15%
--
--
FAQs
What is Janux Therapeutics Inc's expected revenue for the next quarter?
Janux Therapeutics Inc's expected revenue is 7.75M.
What is Janux Therapeutics Inc's price target?
Analysts forecast that Janux Therapeutics Inc's price target is USD 36.39, with the highest forecast at USD 100.00 and the lowest forecast at USD 14.00.
How have Janux Therapeutics IncJANX's recent earnings per share performed?
The market expectation was USD -0.35, while Janux Therapeutics IncJANX's earnings per share (EPS) for the previous quarter was USD -0.39. EPS for the next quarter is expected at USD -0.47.
What is the analyst rating for Janux Therapeutics Inc?
Based on the ratings of Janux Therapeutics Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.